共 50 条
- [1] Validation of duodenal targeting by oral pharmacologic duodenal exclusion therapy for treatment of type 2 diabetesDIABETOLOGIA, 2022, 65 (SUPPL 1) : S102 - S102Carlson, T.Nimgaonkar, A.Guerina, T.Colbert, K.Polomoscanik, S.Petersen, J.Jozefiak, T.Fineman, M.
- [2] GLY-200 (Oral Pharmacologic Duodenal Exclusion) Reduces Bodyweight and Glucose in Patients with T2DOBESITY, 2023, 31 : 39 - 39Bryant, ChristineColbert, KevinPetersen, JohnJozefiak, ThomasNimgaonkar, AshishFineman, Mark
- [3] GLY-200 (Oral Pharmacologic Duodenal Exclusion) Reduces Appetite and Food Intake in Patients with T2DOBESITY, 2023, 31 : 178 - 178Bryant, ChristineNimgaonkar, AshishFineman, Mark
- [4] Chronic Oral Polymeric Duodenal Exclusion Therapy Has Profound Metabolic Benefits in a T2D Rat Model and Affects Duodenal Morphological Enteroplasticity Similar to RYGB surgery: Implications for T2D TherapyDIABETES, 2022, 71Nimgaonkar, AshishGuerina, FlorenceKelleher, Shannon L.Carlson, TaylorColbert, KevinPolomoscanik, StevenPetersen, John S.Habegger, Kirk M.Pasricha, Pankaj J.Fineman, MarkJozefiak, Thomas H.
- [5] GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Reduces Glucose and Bodyweight in Patients with Type 2 DiabetesDIABETES, 2024, 73Fineman, MarkColbert, KevinPetersen, John S.Jozefiak, Thomas H.Nimgaonkar, AshishBryant, Christine
- [6] Profound Metabolic Benefits Observed in an Eight -Week GK Rat Study of a Novel Orally Administered Polymeric Duodenal Exclusion Therapy: Implications for Type 2 Diabetes (T2D) TherapyDIABETES, 2021, 70Nimgaonkar, AshishPolomoscanik, StevenPasricha, Pankaj J.Colbert, KevinJozefiak, Thomas H.Vora, JitenVieira, MarcelaCarlson, TaylorLiu, LianshengKulkarni, SubhashPetersen, John S.
- [7] GLY-200 (Oral Pharmacologic Duodenal Exclusion Drug) Improves Glycemic Control as Measured by CGM in Patients with Type 2 DiabetesDIABETES, 2024, 73Nimgaonkar, AshishBryant, ChristineFineman, Mark
- [8] Oral Pharmacologic Treatment of Type 2 DiabetesANNALS OF INTERNAL MEDICINE, 2017, 166 (04) : I18 - I18Barry, M. J.Humphrey, L. L.Forciea, M. A.
- [9] Intestinal Mucus Complexation by an Oral Duodenal Exclusion Treatment for T2DM and ObesityOBESITY, 2023, 31 : 177 - 178Carlson, TaylorBryant, ChristineColbert, KevinPolomoscanik, StevePetersen, JohnJozefiak, ThomasFineman, MarkNimgaonkar, Ashish
- [10] Robust metabolic benefits of a novel orally administered polymeric duodenal exclusion therapy in animal models of type 2 diabetes: an alternative treatment for type 2 diabetesDIABETOLOGIA, 2021, 64 (SUPPL 1) : 222 - 222Nimgaonkar, A.Jozefiak, T.Colbert, K.Carlson, T.Petersen, J.Vieira, M.Kulkarni, S.Pasricha, P. J.Vora, J.Polomoscanik, S.